

Special Issue

Immune Microenvironment and Immunotherapy in Malignant Brain Tumors

Message from the Guest Editors

Immunotherapy has revolutionized cancer treatment in the last decade by demonstrating the power of the immune system to fight against cancer. Although immunotherapy has brought benefits to patients with many cancer types, patients with brain cancer have not yet experienced these benefits. The brain has a unique tissue immune microenvironment, including the blood–brain barrier, unique resident myeloid cells called microglia and neurons. To improve the efficacy of immunotherapy against brain cancer, we need to better understand the immunobiology of these cancers. Emerging data suggest that the interaction of immune cells not only with other immune cells or cancer cells but also with other cell types, such as neurons and blood vessel cells, significantly impacts brain tumor immunity. There are other factors, such as sex and age, that also could have a significant impact on brain tumor immunity. This Special Issue aims to provide comprehensive information on the current understanding of the immune microenvironment of brain cancer, both primary and metastatic, and potential immunotherapeutic approaches.

Guest Editors

Dr. Masaki Terabe

National Cancer Institute (NCI), Bethesda, MD, USA

Prof. Dr. Mark R. Gilbert

National Cancer Institute (NCI), Bethesda, MD, USA

Deadline for manuscript submissions

25 July 2025



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 8.0
Indexed in PubMed



mdpi.com/si/212907

Cancers

MDPI, Grosspeteranlage 5

4052 Basel, Switzerland

Tel: +41 61 683 77 34

cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 8.0
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)